Adam C. LaRock is a director in Sterne Kessler’s Trial & Appellate Practice Group. Adam concentrates his practice on complex patent litigation, with a special emphasis on pharmaceutical patent litigation under the Hatch-Waxman Act. Adam has worked on cases involving pharmaceuticals (new drug compounds, enantiomers, prodrugs, salt forms, solid state forms, combinations, formulations, methods of treatment), electromechanical apparatuses, diagnostic gene testing, and near-field communication devices. He has experience in all stages of litigation—pre-suit investigation, injunction practice, fact and expert discovery, claim construction, and motion practice, including dispositive-motion practice. Adam has also served as an integral member of multiple trial teams and has experience preparing and examining trial witnesses.
In addition to his work in district courts, Adam has experience in contested proceedings before the Patent Trial and Appeal Board, as well as appeals before the Federal Circuit.
Adam received his B.S. in chemistry from Clarkson University with Great Distinction, and his J.D. from the University of New Hampshire School of Law, Franklin Pierce Center for Intellectual Property. Adam served for two years as an articles editor for IDEA: The Intellectual Property Law Review. During law school, he also interned at the Merrimack County Superior Court as a law clerk for Hon. Carol Ann Conboy and at the New Hampshire Attorney General’s Office. Before joining Sterne Kessler, Adam practiced as a patent litigator in New York City with particular emphasis on Hatch-Waxman cases.
- Represented generic pharmaceutical company in Hatch-Waxman case concerning platelet-aggregation inhibitor.
- Represented generic pharmaceutical company in Hatch-Waxman case concerning laxative formulation.
- Represented brand pharmaceutical company in multiple Hatch-Waxman cases and IPR proceeding concerning combination allergy drug.
- Represented electronics company in an appeal from IPR proceeding concerning near-field communication devices.
- Represented generic pharmaceutical company in Hatch-Waxman case concerning an enzyme inhibitor used to treat COPD.
- Represented generic pharmaceutical company in Hatch-Waxman case concerning leading proton-pump inhibitor.
- Represented generic pharmaceutical company in Hatch-Waxman case concerning leading antipsychotic drug.
- Represented utility services company in district-court litigation concerning stray-voltage-detection-apparatus patents and also in an appeal from IPR proceeding.
- Represented biotechnology company in district court litigation concerning diagnostic gene testing patents.
- Represented generic pharmaceutical company in Hatch-Waxman case concerning antibacterial drug.
- Represented brand pharmaceutical company and university in multiple Hatch-Waxman cases concerning nucleoside analog reverse transcriptase inhibitor used to treat HIV infection.